Dr. Nadia Ovchinsky
Pediatric Gastroenterology (Pediatric Transplant Hepatology Physician)
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Transplant Hepatology Physician primary
NY license 232668 -
Pediatric Gastroenterology Physician
NY license 232668
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $714 in total to this clinician.
| Ipsen Pharma Sas | $282 |
|---|---|
| Mirum Pharmaceuticals, Inc. | $264 |
| Gilead Sciences, Inc. | $146 |
| Genzyme Corporation | $21.40 |
| Food and Beverage | $432 |
|---|---|
| Travel and Lodging | $282 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Pharma Sas May 7, 2025 | Travel and Lodging Bylvay · Gastroenterology · travel to Amsterdam, Netherlands · in-kind | $282 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $203,470 in research payments for these studies, mostly to the institutions running them.
- Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Albireo Pharma, Inc. · Active, not recruiting · NCT05035030 - An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
Albireo Pharma, Inc. · Active, not recruiting · NCT05426733 - An Extension Study of Maralixibat in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (MARCH-ON)
Mirum Pharmaceuticals, Inc. - A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Ipsen Pharma Sas · Recruiting · NCT06850038 - Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
Albireo Pharma, Inc. · Completed · NCT04336722
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.